GH Research PLC (GHRS)
NASDAQ
$23.84−$0.6100 (−2.49%) on the dayAs of the close; data may be delayed.
GHRS price, last 12 months
Key stats
- Previous close
- $24.45
- Open
- $24.48
- Day range
- $23.49 – $24.55
- 52-week range
- $12.04 – $31.44
- Volume
- 180K
- Avg volume (20 days)
- 199K
- Market cap
- $1.6B
Performance
1W−15.6%
1M−17.8%
3M−15.5%
6M+69.2%
YTD+87.7%
1Y+71.4%
vs S&P 500, 1Y+54.6 pts
Technicals and fundamentals
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
- Listed on
- NASDAQ
- Market cap
- $1.6B